Phase 2 Study of MEDI4736 in Patients With Glioblastoma

Clinical Trial ID NCT02336165

PubWeight™ 11.24^‹?›

🔗 Visit the ClinicalTrials.gov page for NCT02336165

Top papers

Rank	Title	Journal	Year	PubWeight™‹?›
1	Prospects of immune checkpoint modulators in the treatment of glioblastoma.	Nat Rev Neurol	2015	1.50
2	Current status and perspectives in translational biomarker research for PD-1/PD-L1 immune checkpoint blockade therapy.	J Hematol Oncol	2016	1.12
3	What next for newly diagnosed glioblastoma?	Future Oncol	2015	0.94
4	Overview of current immunotherapeutic strategies for glioma.	Immunotherapy	2015	0.89
5	Immunotherapy for cancer in the central nervous system: Current and future directions.	Oncoimmunology	2015	0.88
6	Stereotactic radiation therapy combined with immunotherapy: augmenting the role of radiation in local and systemic treatment.	Oncology (Williston Park)	2015	0.85
7	Novel cancer antigens for personalized immunotherapies: latest evidence and clinical potential.	Ther Adv Med Oncol	2016	0.81
8	Trial Watch: Immunotherapy plus radiation therapy for oncological indications.	Oncoimmunology	2016	0.81
9	Current clinical trials testing the combination of immunotherapy with radiotherapy.	J Immunother Cancer	2016	0.81
10	Replication and validation of higher order models demonstrated that a summary score for the EORTC QLQ-C30 is robust.	J Clin Epidemiol	2015	0.80
11	Combining Radiation Therapy with Immune Checkpoint Blockade for Central Nervous System Malignancies.	Front Oncol	2016	0.78
12	Current status and future directions of anti-angiogenic therapy for gliomas.	Neuro Oncol	2015	0.77
13	Immunotherapy for neuro-oncology: the critical rationale for combinatorial therapy.	Neuro Oncol	2015	0.75
14	Perspectives on investigational drugs and immunotherapies for glioblastoma.	Expert Opin Investig Drugs	2016	0.75